Tag: 2026

PTPRN2 hypomethylation and PHB2-associated miR-153-3p maturation define dual epigenetic features linked to symptom variability in Myalgic encephalomyelitis

Abstract:

Background: Myalgic encephalomyelitis (ME) is a chronic, debilitating condition increasingly linked to epigenetic changes. With its unclear pathophysiology and no validated diagnostic biomarkers, DNA methylation becomes of interest. Specifically, DNA methylation patterns in saliva, to study ME-related epigenetic changes.

Methods: Saliva samples from 54 ME patients and 21 sedentary healthy controls were analyzed by DNA methylation array. Symptom assessment was conducted using validated questionnaires (SF-36, MFI-20, and DSQ).

Results: A significant DNA hypomethylation at the CpG site cg19803194 (Bonferroni-corrected and adjusted for saliva composition, p = 2.14 × 10− 7) within the PTPRN2 gene body was identified. This hypomethylation was associated with cognitive impairments in both sexes, such as difficulties expressing thoughts and comprehension, commonly known as “brain fog,” and respiratory symptoms in male patients. The hypomethylation also corresponded with reduced circulating levels of miR-153-3p, an intronic microRNA of PTPRN2, which was associated with impaired memory recall in both sexes. Interestingly, the mitochondrial protein Prohibitin 2 (PHB2) was associated with reduced miR-153-3p activity. This association was consistent with a predominant cytoplasmic localization of PHB2 and selective reduction of mature miR-153-3p without changes in its immature forms, suggesting involvement at a post-transcriptional stage that may be attenuated in female patients due to increased extracellular export of PHB2.

Conclusions: These findings suggest a potential epigenetic relationship in ME involving PTPRN2 body hypomethylation and PHB2-associated variation in miR-153-3p levels. While the directionality between gene-body methylation and expression remains a biological hypothesis, these results shed light on potential molecular pathways associated with symptom variability and sex differences in ME severity.

Source: Chalder L, Elremaly W, Li D, Fang Y, Caraus I, Leveau C, Elbakry M, Franco A, Godbout C, Di Tomasso G, Nepotchatykh E, Rostami-Afshari B, Gimenez M, Legault P, Moreau A. PTPRN2 hypomethylation and PHB2-associated miR-153-3p maturation define dual epigenetic features linked to symptom variability in Myalgic encephalomyelitis. J Transl Med. 2026 Apr 20. doi: 10.1186/s12967-026-08162-6. Epub ahead of print. PMID: 42010606. https://link.springer.com/article/10.1186/s12967-026-08162-6 (Full text available as PDF file)

Comparing ME/CFS following mononucleosis with Long COVID

Abstract:

Objectives: Long COVID following SARS-CoV-2 and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) following infectious mononucleosis (IM) are examples of post-infectious chronic illnesses. Behavioral and pathophysiological underpinnings of both ME/CFS following IM and Long COVID are not well understood.

Methods: We studied ME/CFS development following IM in a diverse group of college students who were enrolled before the onset of IM. We categorized those meeting either moderate or severe ME/CFS criteria. We subsequently recruited a matched sample of those infected with SARS-CoV-2, some of whom recovered and others of whom developed Long COVID. We compared and contrasted ME/CFS and Long COVID following IM and SARS-CoV-2 infection in terms of somatic symptoms, coping strategies, depression and anxiety symptoms, and functional status.

Results: In general, the Long COVID group’s symptom burden was less than that of the Severe ME/CFS group but more than that of the Moderate ME/CFS group.

Discussion: These findings may allow investigators a better understanding of these post-viral illness pathophysiologies.

Source: Jason LA, Furst J, Katz BZ. Comparing ME/CFS following mononucleosis with Long COVID. Chronic Illn. 2026 Apr 15:17423953251347108. doi: 10.1177/17423953251347108. Epub ahead of print. PMID: 41984971. https://pubmed.ncbi.nlm.nih.gov/41984971/

Testing a Personalised Dysautonomia Management Protocol in Patients with Orthostatic Intolerance and a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or Long COVID

Abstract:

Background/Objectives: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID (LC) are complex multisystem conditions with significant functional disability. Many patients experience symptoms of orthostatic intolerance, which can be captured in some cases as Orthostatic Hypotension (OH) or Postural orthostatic Tachycardia Syndrome (PoTS) on objective testing. Conservative treatments are recommended for first-line symptom management, but there is a lack of efficacy evidence. This study aims to assess the feasibility of an 8-week clinically supervised, personalised Dysautonomia Management Protocol (DMP) in a cohort of ME/CFS and LC patients with subjective and objective evidence of orthostatic intolerance (dysautonomia).

Methods: ME/CFS and LC patients with objective dysautonomia on the 10 min active Lean Test (LT) were recruited to an 8-week DMP, with interventions introduced cumulatively every two weeks. Interventions included increasing daily fluid intake to 3 litres and salt intake to 10 g, pacing to avoid crashes and calf activation. Baseline and weekly data collection included the LT, Composite Autonomic Symptom Score questionnaire (COMPASS-31) and Yorkshire Rehabilitation Scale (YRS).

Results: Sixteen participants completed the 8-week program, five discontinued during the program, and one was withdrawn following a severe crash. The COMPASS-31 improved by 7.7 points from week 1 to week 8 (p = 0.045), with a medium Cohen’s d effect size of 0.55. For the same period, there was a non-significant (p = 0.16) improvement in the YRS symptom severity score by 2 points. Comparing the final two weeks of the program with the first two weeks, mean heart rate during the LT decreased by 4.8 beats per minute (p = 0.032), with a medium Cohen’s d effect size of 0.44. Adherence to the interventions was highly variable, with none of the patients able to fully employ all four recommendations.

Conclusions: The results suggest that targeted conservative interventions could influence autonomic function and symptom reduction. However, the magnitude of change was limited, and statistical significance might not necessarily relate to a clinically significant improvement in symptoms.

Source: Barr J, Marsden L, Dassanayake T, Almutairi N, McKeever V, Gaber T, Tarrant R, Godfrey B, Witton S, Sivan M. Testing a Personalised Dysautonomia Management Protocol in Patients with Orthostatic Intolerance and a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or Long COVID. J Clin Med. 2026 Mar 25;15(7):2510. doi: 10.3390/jcm15072510. PMID: 41976810. https://www.mdpi.com/2077-0383/15/7/2510 (Full text)

Pathophysiological, Translational, and Diagnostic Aspects of ME/CFS: A Focus on Skeletal Muscle Involvement

Abstract:

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic, multisystemic disorder characterized by severe, persistent fatigue not alleviated by rest and worsened by minimal exertion, often accompanied by post-exertional malaise (PEM), unrefreshing sleep, cognitive dysfunction, and autonomic disturbances. Despite decades of research, its pathophysiology remains incompletely understood, and skeletal muscle involvement has only recently gained attention.

This review aims to provide a historical and pathophysiological synthesis of ME/CFS, emphasizing the pivotal role of skeletal muscle in the onset and persistence of symptoms, and to integrate molecular, cellular, and pathophysiological evidence into a coherent explanatory framework.

This is a narrative review of published literature (1990-2025) with critical integration of clinical, biochemical, and experimental data on oxidative stress, mitochondrial dysfunction, Excitation-Contraction (E-C coupling) dysregulation, and muscle secretome alterations in ME/CFS also in relation to post-viral syndromes (e.g., Long COVID).

Evidence consistently points to mitochondrial oxidative stress, redox imbalance, impaired Ca2+ handling, and altered signaling pathways in skeletal muscle of patients with ME/CFS. Historical milestones show an evolution from psychogenic interpretations toward recognition of ME/CFS as a biological disorder with neuromuscular and metabolic underpinnings.

ME/CFS can be interpreted as a skeletal muscle-metabolic disorder characterized by oxidative distress, mitochondrial dysfunction, and impaired energy regulation, leading to the clinical picture of exercise intolerance and post-exertional malaise. Integrating basic and clinical research through a translational approach provides the foundation for new diagnostic tools, targeted therapies, and biomarkers.

Source: Fanò-Illic G, Coscia F, Gigliotti PV, Checcaglini F, Carraro U, Fulle S, Mancinelli R. Pathophysiological, Translational, and Diagnostic Aspects of ME/CFS: A Focus on Skeletal Muscle Involvement. Diagnostics (Basel). 2026 Mar 28;16(7):1019. doi: 10.3390/diagnostics16071019. PMID: 41975732. https://www.mdpi.com/2075-4418/16/7/1019 (Full text)

Commentary: Cognitive behavioural therapy for the treatment of chronic fatigue syndrome in adults: a short analysis of the meta-analysis

Introduction:

The meta-analysis by Kolala et al. () selected 12 studies and examined whether non-protocol-based cognitive behavioural therapy (CBT) is effective in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients who have not been selected in accordance with the Oxford criteria. They chose this approach because experts have recommended that the Oxford criteria should not be used anymore because post-exertional malaise (PEM), the main characteristic of the disease, is not required for diagnosis according to these criteria.

The primary outcome of the meta-analysis was fatigue, and the authors concluded that CBT did not lead to statistically significant improvement. Nevertheless, at the same time, they concluded that individual face-to-face CBT had a large effect on reducing fatigue and that self-directed CBT had a large effect on increasing physical functioning. None of their other analyses yielded statistically significant results.

They also concluded that self-directed CBT should be used for patients with milder symptoms and that booster sessions may be required because of the lack of long-term efficacy of CBT. However, in a poster presentation for the Royal Australian and New Zealand College of Psychiatrists, they stated that CBT should be offered to all patients with ME/CFS ().

The British National Institute for Health and Care Excellence (NICE) reviewed the literature as part of the process to update its ME/CFS guideline and concluded that CBT studies were all of low or very low quality. NICE () also concluded that CBT does not lead to improvement or recovery.

In this article, we analysed the evidence that was used by Kolala et al. () to come to their conclusions. Our analysis, however, shows that the data support the conclusions by NICE and that it does not support the conclusions of the meta-analysis. Moreover, Kolala et al. ignored the problems of the studies in their analysis.

Source: Vink M, Vink-Niese F. Commentary: Cognitive behavioural therapy for the treatment of chronic fatigue syndrome in adults: a short analysis of the meta-analysis. Front Psychiatry. 2026 Mar 27;16:1746712. doi: 10.3389/fpsyt.2025.1746712. PMID: 41969360; PMCID: PMC13067286. https://pmc.ncbi.nlm.nih.gov/articles/PMC13067286/ (Full text)

Making Invisible Illnesses Visible: Recognizing and Responding to Infection Associated Chronic Conditions

Abstract:

The emergence of post-COVID conditions (PCC) has renewed attention to infection-associated chronic conditions and illnesses (IACCI), including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Lyme disease-associated chronic symptoms. Millions of Americans are affected by these debilitating, misunderstood conditions, which share symptom profiles and pathophysiologic abnormalities. IACCI have received insufficient clinical attention and research investment.

We outline elements of a patient-centered approach to care, emphasizing validation of patients’ experiences, multidisciplinary management, and symptom-focused treatment. Opportunities to strengthen clinical practice include a new CMS code for chronic condition management, extended visits, and creation of welcoming care environments. Advances in PCC and ME/CFS research provide a foundation for exploring shared mechanisms and developing targeted therapies. Improved surveillance, harmonized research, and inclusive trial designs are needed to define disease burden and accelerate therapeutic progress. Coordinated action by clinicians, researchers, and policymakers can help address longstanding gaps and improve outcomes for all individuals with IACCI

Source: Iskander JK, Haridopolos S. Making Invisible Illnesses Visible: Recognizing and Responding to Infection Associated Chronic Conditions. Clin Infect Dis. 2026 Apr 9:ciag240. doi: 10.1093/cid/ciag240. Epub ahead of print. PMID: 41967005. https://pubmed.ncbi.nlm.nih.gov/41967005/

Preventive Effects of Probiotic Formula on Metabolic Stress Associated Physical Fatigue in Forced Swimming and LPS-Induced Mouse Models

Abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disorder characterized by persistent fatigue and post-exertional symptom exacerbation, frequently associated with immune and metabolic disturbances. To evaluate the therapeutic potential of a probiotic formula, HH-205M, we employed a composite mouse model combining forced swimming stress (FSS) and repeated lipopolysaccharide (LPS) administration. FSS-LPS exposure induced pronounced fatigue-like phenotypes, including reduced physical endurance capacity in treadmill and weight-loaded swimming tests, delayed recovery in post-swim grooming behavior, and increased thermal pain sensitivity.

These behavioral impairments were accompanied by elevated serum creatine kinase (CK), lactate dehydrogenase (LDH), and lactate levels, indicating systemic metabolic stress. At the tissue level, FSS-LPS increased lipid peroxidation and upregulated pro-inflammatory cytokine expression while suppressing antioxidant gene expression in the gastrocnemius muscle. Furthermore, expression of lactate-related genes, Hcar1 (GPR81) and Slc16a1 (MCT1), was reduced, suggesting disruption of lactate transport and sensing pathways under chronic stress and inflammatory conditions.

HH-205M supplementation attenuated the elevations in circulating fatigue-related biomarkers, moderated oxidative and inflammatory responses, and restored Hcar1 and Slc16a1 expression.

These molecular changes were paralleled by improvements in endurance performance and nociceptive sensitivity. HH-205M administration was also associated with distinct shifts in gut microbial composition, including enrichment of Akkermansia and Bacteroides and reduced relative abundance of Alistipes.

Collectively, these findings indicate that the FSS-LPS composite model recapitulates inflammation-associated metabolic disturbances relevant to fatigue-like conditions and that HH-205M administration is associated with concurrent improvements in behavioral and molecular parameters in this model.

Source: Song JG, Bae HJ, Lee DH, Seo J, Lee B, Shin KJ, Chung EC, Lee J, Kim HW, Oh NS. Preventive Effects of Probiotic Formula on Metabolic Stress Associated Physical Fatigue in Forced Swimming and LPS-Induced Mouse Models. J Microbiol Biotechnol. 2026 Apr 10;36:e2603034. doi: 10.4014/jmb.2603.03034. PMID: 41958144. https://pubmed.ncbi.nlm.nih.gov/41958144/

Validation of the Wood Mental Fatigue Inventory in adolescents with myalgic encephalomyelitis/chronic fatigue syndrome

Abstract:

Background: There is no consensus regarding the most reliable and valid measures of cognitive dysfunction in adolescents and adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The Wood Mental Fatigue Inventory (WMFI) is commonly used in adults while the Pediatric Quality of Life Multidimensional Fatigue Scale (PedsQL MFS) is commonly used in adolescents. This study examined whether the WMFI was valid in adolescents.

Methods: Over a two-year period, participants in a cohort study completed four questionnaires: PedsQL, PedsQL MFS, Functional Disability Inventory (FDI), and WMFI. We examined the validity of the WMFI in 55 healthy adolescents and 55 with ME/CFS, determined how well the WMFI and PedsQL MFS cognitive fatigue subscale correlated with one another and with general quality of life surveys, and examined each questionnaire’s responsiveness to change over time.

Results: The PedsQL MFS cognitive fatigue subscale and the WMFI had a strong negative correlation for both healthy controls and ME/CFS patients at baseline with R2 values of 0.3915 and 0.8049 respectively. There was a similar strong negative correlation (R2 = 0.7739) between the two questionnaires in ME/CFS participants at the 24 month point of follow-up after multi-modal treatment. Each questionnaire was found to be similarly responsive to change.

Conclusion: The WMFI had a high correlation with the PedsQL MFS cognitive fatigue subscale. The WMFI has the advantage of ease of scoring. Both measures were responsive to changes in mental fatigue among those with ME/CFS over time.

Source: Welch DC, Edwards CC, Broussard CA, Swope ME, Christoforou ME, Matson PA, Azola AM, Rowe PC. Validation of the Wood Mental Fatigue Inventory in adolescents with myalgic encephalomyelitis/chronic fatigue syndrome. Brain Behav Immun Health. 2026 Mar 25;53:101222. doi: 10.1016/j.bbih.2026.101222. PMID: 41953581; PMCID: PMC13053862. https://pmc.ncbi.nlm.nih.gov/articles/PMC13053862/ (Full text)

The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID: An Adaptive Randomized Trial

Abstract:

Background: Postacute sequelae of SARS-CoV-2, or long COVID, presents a major therapeutic challenge, with fatigue being a prevalent and debilitating symptom.

Objective: To assess the efficacy of fluvoxamine and metformin for long COVID fatigue.

Design: Randomized, placebo-controlled, adaptive trial. (ClinicalTrials.gov: NCT06128967).

Setting: Outpatient sites in Brazil.

Participants: 399 adults with fatigue persisting 90 or more days after confirmed SARS-CoV-2 infection.

Intervention: Participants were randomly assigned to fluvoxamine (100 mg twice daily), metformin (750 mg twice daily), or matching placebo for 60 days.

Measurements: The primary outcome was change in Fatigue Severity Scale (FSS) score.

Results: Fluvoxamine showed a significant reduction in fatigue compared with placebo at day 60 (mean difference, -0.43 [95% credible interval {CrI}, -0.80 to -0.07]), with a sustained effect at day 90 (mean difference, -0.58 [CrI, -0.98 to -0.16]). Fluvoxamine also improved quality-of-life scores with high posterior probability. Metformin showed no significant benefit. Adverse events were less frequent with fluvoxamine (20.0%) than with metformin (28.8%) or placebo (29.7%). Grade 3 and higher adverse events were rare across all groups.

Limitations: The 90-day follow-up period limits conclusions about the durability of treatment effects, and the exclusive focus on fatigue as the primary outcome does not address other prevalent long COVID symptoms, leaving fluvoxamine’s broader therapeutic utility uncertain.

Conclusion: Fluvoxamine, but not metformin, may be an effective treatment for reducing fatigue and improving quality of life in patients with long COVID.

Primary funding source: The Latona Foundation.

Source: Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Ferreira TS, Reis LLF, Figueiredo Guimaraes Almeida AP, Menezes Amaral M, Savassi LCM, de Souza Campos VH, Campos Simplicio MI, Barra Ribeiro L, de Souza Medeiros T, Campos Siqueira T, Vieira TS, Drumond Rausse N, Garofolo TC, Fagundes Silva EC, Harari O, D’Urso G, Forrest JI, Park J, Nachega JB, Lindsell C, Glenn JS, Thorlund K, Dybul M, Mills EJ; REVIVE Investigators. The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial. Ann Intern Med. 2026 Mar 31. doi: 10.7326/ANNALS-25-03959. Epub ahead of print. PMID: 41911553. https://www.acpjournals.org/doi/10.7326/ANNALS-25-03959 (Full text)

Babesia and Bartonella Species DNA in Blood and Enrichment Blood Cultures from People with Chronic Fatigue and Concurrent Neurological Symptoms

Abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a medical condition characterized by extreme fatigue lasting at least 6 months. Based upon case reports, patients infected with Babesia or Bartonella spp. have reported a history of chronic fatigue and concurrent neurological symptoms. In this study, 50 study participants reporting fatigue lasting from six months to 19 years and one or more neurological symptoms were selected.

PCR assays were used to amplify Babesia and Bartonella spp. DNA from blood and enrichment blood cultures. Using targeted qPCR amplification and DNA sequencing, infection with Babesia spp., Bartonella spp. or both genera was confirmed in 10, 11, and 2 individuals, respectively. Of 50 participants, 12 (24%, 95% CI: 12-36%) were infected with a Babesia species, while Bartonella species infection was documented in 13/50 individuals (26%, 95% CI: 13.8-38.2%).

This study provides documentation supporting a potential role for Babesia and Bartonella infection in patients with presentations consistent with ME/CFS. Prospective case-control studies, using highly sensitive direct pathogen detection techniques, are needed to determine whether or the extent to which infection with members of these two genera contributes to or causes ME/CFS.

Source: Breitschwerdt EB, Maggi RG, Bush JC, Kingston E. Babesia and Bartonella Species DNA in Blood and Enrichment Blood Cultures from People with Chronic Fatigue and Concurrent Neurological Symptoms. Pathogens. 2025 Dec 19;15(1):2. doi: 10.3390/pathogens15010002. PMID: 41598986; PMCID: PMC12844623. https://pmc.ncbi.nlm.nih.gov/articles/PMC12844623/ (Full text)